共查询到20条相似文献,搜索用时 15 毫秒
1.
Jun Yang Daniel Ka Leung Cheuk Shau Yin Ha Alan Kwok Shing Chiang Tsz Leung Lee Marco Hok Kung Ho Godfrey Chi Fung Chan 《Pediatric transplantation》2012,16(7):771-778
Yang J, Cheuk DKL, Ha SY, Chiang AKS, Lee TL, Ho MHK, Chan GCF. Infliximab for steroid refractory or dependent gastrointestinal acute graft‐versus‐host disease in children after allogeneic hematopoietic stem cell transplantation. Abstract: aGVHD of the GI tract is common after allogeneic HSCT. Corticosteroids are the mainstay of treatment. Recent data suggest infliximab might be beneficial for steroid refractory aGVHD. We reviewed our experience in 10 pediatric patients who developed severe steroid refractory aGVHD (stage 3, n = 6; stage 4, n = 4), after an allogeneic matched unrelated HSCT for various hematological diseases (leukemia, n = 7; thalassemia, n = 3). The median age was 9.5 yr (range, 0.8–18.5 yr). All patients received 10 mg/kg infliximab weekly for 3–4 doses. Eight patients had CR and two had partial response. None of the patients developed therapy‐related adverse effects. All patients developed infections subsequently, which may or may not be related to infliximab. Five patients developed chronic GVHD (cGVHD) (four severe, one mild). Six patients died at 66–1451 days post‐transplant, from infection (n = 3), aGVHD (n = 1), lung cGVHD (n = 1), or idiopathic pneumonia (n = 1). Four patients were alive at 238–924 days post‐transplant, all of whom had an increase in BMI by six months post‐transplant. In conclusion, infliximab is well tolerated and appears effective in children with steroid refractory or dependent GI aGVHD. Infection is common and mortality remains high. 相似文献
2.
3.
4.
Successful treatment with placenta‐derived decidual stromal cells in a pediatric patient with life‐threatening acute gastrointestinal graft‐versus‐host disease 下载免费PDF全文
Britt Gustafsson Per Frisk Attilla Szakos Behnam Sadeghi Olle Ringdén Britt‐Marie Frost 《Pediatric transplantation》2017,21(5)
Severe aGvHD is a life‐threatening complication after allogeneic HSCT. The GI tract is considered to play a key role in aGvHD, where the disease process can start and is one of the major target organs. Here, we present a case of a one‐year‐old child with a life‐threatening GI‐aGvHD stage IV, post‐HSCT, resistant to steroids and MMF for 4 weeks. He was successfully treated with placenta‐derived DSC. 相似文献
5.
Coronary artery involvement in chronic graft‐versus‐host disease presenting as sudden cardiac arrest
Graft‐versus‐host disease (GVHD) is related to considerable morbidity and mortality after allogeneic hematopoietic stem cell transplantation (HSCT). Cardiac complications associated with GVHD are uncommon, and coronary artery involvement is even more unusual. We report on a male pediatric patient with chronic GVHD who developed a fatal ventricular arrhythmia caused by coronary artery obstruction after HSCT. At 30 months after HSCT, he suddenly collapsed with ventricular fibrillation. After resuscitation, electrocardiography showed abnormal q‐wave and ST changes in the inferior leads, suggesting a coronary event. Coronary angiography revealed complete obstruction of the proximal left anterior descending artery, subtotal obstruction of the mid left circumflex artery, and mild narrowing at the right coronary artery. This boy had none of the risk factors for coronary artery disease, and the only possible explanation for the cardiac event is GVHD. Coronary artery disease only rarely occurs as a cardiac event in children. However, coronary artery involvement should be recognized as one of the important manifestations of chronic GVHD in children. 相似文献
6.
Nutritional risk factors predict severe acute graft‐versus‐host disease and early mortality in pediatric allogeneic hematopoietic stem cell transplantation 下载免费PDF全文
Eva H. Kerby Yimei Li Kelly D. Getz Elizabeth C. Smith Laura T. Smith Nancy J. Bunin Alix E. Seif 《Pediatric blood & cancer》2018,65(2)
7.
Gassas A, Zaidman I, Schechter T, Doyle J. Beyond gastrointestinal graft‐versus‐host disease. A lesson to learn.Pediatr Transplantation 2011: 15: E139–E141.© 2010 John Wiley & Sons A/S. Abstract: The authors present a child with severe GvHD of GI tract with typical presentation of ileus and abdominal pain. However, the severe GvHD has led to multiple intermittent intussusceptions with resultant ischemic segments of the small bowel leading to sub‐acute mechanical intestinal obstruction. The clinical presentation of the mechanical intestinal obstruction was identical to the preceding ileus GvHD presentation. This has led to continuation of the conservative management with immunosuppressant therapy and delaying further investigation and surgical intervention. Once a barium study demonstrated the severe bowel constriction, laparoscopic surgical resection was necessary with excellent results. The resected small bowel showed multiple segments of ischemic ileitis leading to ulceration and severe stricture. The resection margins showed regenerating mucosa with no ulceration, but with focal evidence of mild GvHD. 相似文献
8.
Extracorporeal photopheresis performed on the CELLEX® compared with the UVAR‐XTS® instrument is more efficient and better tolerated in children with steroid‐refractory graft‐versus‐host disease 下载免费PDF全文
Ekta Kapadia MD Edward Wong MD Evelio Perez‐Albuerne MD David Jacobsohn MD ScM 《Pediatric blood & cancer》2015,62(8):1485-1488
9.
Impact of very early CD4+/CD8+ T cell counts on the occurrence of acute graft‐versus‐host disease and NK cell counts on outcome after pediatric allogeneic hematopoietic stem cell transplantation 下载免费PDF全文
Pasi Huttunen MD PhD Mervi Taskinen MD PhD Sanna Siitonen MD PhD Ulla M. Saarinen‐Pihkala MD PhD 《Pediatric blood & cancer》2015,62(3):522-528
10.
11.
Pooja Khandelwal Julia Lawrence Alexandra H. Filipovich Stella M. Davies Jacob J. Bleesing Michael B. Jordan Parinda Mehta Sonata Jodele Michael S. Grimley Ashish Kumar Kasiani Myers Rebecca A. Marsh 《Pediatric transplantation》2014,18(1):94-102
SR‐aGVHD remains a significant cause of morbidity and mortality in allogeneic HCT recipients. Alemtuzumab has been used with success in adult patients but has not been studied in the pediatric setting. To estimate the effectiveness of alemtuzumab for the treatment of SR‐aGVHD in pediatric patients, we retrospectively reviewed the charts of 19 patients (median age 4 yr, range 0.5–28 years) with grades II (n = 3), III (n = 10), or IV (n = 6) SR‐aGVHD who received alemtuzumab treatment. Patients received a median dose of 0.9 mg/kg alemtuzumab (range 0.3–2 mg/kg) divided over 2–6 days. Eighty‐nine percent of patients received additional courses. A complete response, defined as GVHD of grade 0 at four wk following the first alemtuzumab course, was observed in nine patients (47%). A partial response, defined as an improvement in grade after four wk, was observed in five patients (26%). There was no response in five patients (26%). The overall response rate at four wk was 73%. Infectious complications included bacteremia (47%), presumed or documented fungal infections (21%), adenovirus viremia (52%), EBV viremia (36%), and CMV viremia (36%). We conclude that alemtuzumab is effective for SR‐aGVHD in pediatric patients with a tolerable spectrum of complications. 相似文献
12.
13.
Infusion‐related febrile reaction after haploidentical stem cell transplantation in children is associated with higher rates of engraftment syndrome and acute graft‐versus‐host disease 下载免费PDF全文
Yao Chen Xiao‐Jun Huang Kai‐Yan Liu Huan Chen Yu‐Hong Chen Xiao‐Hui Zhang Feng‐Rong Wang Wei Han Jing‐Zhi Wang Yu Wang Chen‐Hua Yan Yuan‐Yuan Zhang Yu‐Qian Sun Lan‐Ping Xu 《Pediatric transplantation》2015,19(8):918-924
The clinical significance and prognostic impact of IRFR in pediatric recipients of haploidentical SCT are not clearly understood. Therefore, we attempted to determine how IRFR affects clinical outcomes in children. Clinical data from 100 consecutive pediatric patients (60 boys and 40 girls; median age, 12 yr [range, 2–18 yr] after haploidentical SCT between January 2010 and December 2012 were collected retrospectively. IRFR was described as unexplained fever (>38 °C) within 24 h after the infusion of haploidentical PBSCs. Thirty‐eight (38.0%) cases met the criteria for IRFR. ES was found in 24 (63.2%) of the 38 children with IRFR, with the median time of developing ES of +9 (7–16) days, while only 15 (25.4%) of the 59 children without IRFR were found with ES (p < 0.001). Similarly, the cumulative incidence rates of grade II–IV aGVHD were 50.0% in the IRFR group and 29.3% (p = 0.012) in the non‐febrile group. Multivariate analysis identified IRFR as the risk factor for ES and aGVHD. In the haploidentical setting, IRFR is associated with the development of ES and aGVHD. We attempted to determine how IRFR affects clinical outcomes in children after haploidentical SCT. Thirty‐eight children comprised the IRFR group, and 59 were in the control (non‐IRFR) group. High incidence of ES was observed in children with the occurrence of IRFR. Similarly, the incidence of stage I–IV and II–IV aGVHD was significantly higher in the febrile group. Multivariate analysis showed IRFR to be the risk factor for ES and aGVHD. 相似文献
14.
Maura Faraci Ilaria Caviglia Erika Biral Giuseppe Morreale Stefano Giardino Lucia Garbarino Elio Castagnola Giorgio Dini Edoardo Lanino 《Pediatric transplantation》2012,16(8):887-893
a‐GvHD may complicate allogeneic HSCT. In this retrospective single‐center study, we evaluated incidence and risk factors of a‐GvHD in 197 consecutive allogeneic pediatric HSCTs applying Glucksberg and NIH a‐GvHD classifications. Among 179 eligible transplants, the cumulative incidence of grade 0–I a‐GvHD was 48% and grade II–IV was 52%. None of the considered variables significantly influenced the incidence of grade II–IV a‐GvHD. Malignancy and myeloablation were associated with an increased risk of classic a‐GvHD (p < 0.01). Seventy‐two percentage of children are alive, with a significant difference in OS and TRM between grade 0 and I vs. grade II and IV a‐GvHD; this observation was reproduced in the non‐malignant setting, while only a disparity in TRM was evidenced in children with malignancy. In our experience, the incidence of a‐GvHD was similar, regardless of donor type. Myeloablation and malignant disease represented the only risk factors for classic a‐GvHD. Our results highlight the need for a better prevention of this complication in the non‐malignant setting. 相似文献
15.
Comparison of continuous and twice‐daily infusions of cyclosporine A for graft‐versus‐host‐disease prophylaxis in pediatric hematopoietic stem cell transplantation 下载免费PDF全文
Katsutsugu Umeda MD Souichi Adachi MD Shiro Tanaka PhD Atsushi Ogawa MD Naoki Hatakeyama MD Kazuko Kudo MD Naoki Sakata MD Shunji Igarashi MD Kumi Ohshima MD Nobuyuki Hyakuna MD Motoaki Chin MD Hiroaki Goto MD Yoshiyuki Takahashi MD Eiichi Azuma MD Katsuyoshi Koh MD Akihisa Sawada MD Koji Kato MD Masami Inoue MD Yoshiko Atsuta MD Akiyoshi Takami MD Makoto Murata MD 《Pediatric blood & cancer》2015,62(2):291-298
16.
Joel A. Brochstein Stephan Grupp Harry Yang Stanley R. Pillemer Gregory P. Geba 《Pediatric transplantation》2010,14(2):233-241
Brochstein JA, Grupp S, Yang H, Pillemer SR, Geba GP. Phase‐1 study of siplizumab in the treatment of pediatric patients with at least grade II newly diagnosed acute graft‐versus‐host disease.Pediatr Transplantation 2010:14:233–241. © 2009 John Wiley & Sons A/S. Abstract: In a phase‐1 study, siplizumab, a humanized anti‐CD2 monoclonal antibody, was administered (0.012 or 0.04 mg/kg) to 10 pediatric patients with ≥ grade‐II newly diagnosed, non‐steroid‐refractory aGvHD after BMT or PBSCT. SAEs and other AEs including infections, and GvHD staging changes (overall, skin, liver, gut) were evaluated over 364 days. Patients reported a total of 121 AEs (19 grade‐3, 5 grade‐4 0.012 mg/kg group; 17 grade‐3, 17 grade‐4 0.04 mg/kg group) and 14 SAEs (five grade‐3, three grade‐4, 0.012 mg/kg group; three grade‐3, 0.04 mg/kg group); 15 AEs in five patients and four SAEs in three patients (fever, PTLD, adenoviral infection, and EBV lymphoma) were considered siplizumab‐related. Six deaths occurred (study days 17–267); two were considered siplizumab‐related: one from EBV‐associated PTLD (0.012 mg/kg) and one from adenoviral infection (0.04 mg/kg); the other four deaths could potentially be attributed in part to study drug Three patients (one, 0.012 mg/kg group; two, 0.04 mg/kg group) developed PTLD. By study day 12, GvHD grade decreased in 3/5 and 2/5 patients in the 0.012 and 0.04 mg/kg groups, respectively; remission (grade 0) occurred in one patient in each group. Four of five patients (0.012 mg/kg group) and one of four patients (0.04 mg/kg group) achieved grade 0 GvHD during the first 100 study days (55.6% response). While treatment with siplizumab was associated with improvement of GvHD and remission in some pediatric patients, the overall high morbidity, mortality, and occurrence of PTLD is of safety concern, not warranting further development of siplizumab for the treatment of aGvHD in children. 相似文献
17.
Graft‐versus‐host disease (GVHD) prophylaxis by using methotrexate decreases pre‐engraftment syndrome and severe acute GVHD,and accelerates engraftment after cord blood transplantation 下载免费PDF全文
Akihiro Iguchi Yukayo Terashita Minako Sugiyama Junjiro Ohshima Tomonobu Z. Sato Yuko Cho Ryoji Kobayashi Tadashi Ariga 《Pediatric transplantation》2016,20(1):114-119
GVHD and graft failure are serious problems in CBT. PES after CBT also occurs frequently and is associated with transplantation‐related complications such as acute GVHD. We reviewed medical records for 70 consecutive child CBT recipients between December 1997 and April 2015. Forty‐nine patients received prophylaxis against GVHD with CsA or Tac in combination with mPSL from day +7 (mPSL group), and 21 patients received CsA or Tac with MTX on day +1 and day +3 (MTX group). Neutrophil engraftment was detected in 59 patients (84.3%). Neutrophil engraftment rate in the MTX group was significantly higher than that in the mPSL group (21/21 (100%) and 38/49 (77.6%), respectively, p = 0.027). PES developed in 35 patients, and the incidence of PES in the mPSL group was significantly higher than that in the MTX group (p = 0.036). The incidence of severe acute GVHD (grade III or IV) in the MTX group was significantly lower than that in the mPSL group (p = 0.049). Although this study was a small‐scale study, the results showed that increase in the rate of engraftment and decrease in the incidence of early immune reactions such as PES and severe acute GVHD could be achieved by early commencement of immunosuppression using MTX. 相似文献
18.